Hormonal
Dual GIP and GLP-1 receptor agonist tirzepatide significantly improves kidney outcomes in adults with type 2 diabetes and increased cardiovascular risk compared to insulin.
If you have Type 2 Diabetes and are at risk for kidney disease, ask your doctor about tirzepatide. It is a once-weekly injection that has been shown to significantly reduce the risk of serious kidney problems compared to insulin, while also helping with blood sugar and weight control. You do not need to adjust the dose even if you have kidney disease.
Preliminary results also suggest that tirzepatide strongly improves kidney function compared to insulin in adults with T2DM with increased cardiovascular risk.
Why this rating
Based on Phase 3 trial data (SURPASS) comparing tirzepatide to insulin, showing significant hazard ratios.
Source
Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
Tomislav Bulum · Biomedicines · 2022
DOI 10.3390/biomedicines10102586
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →